Evidence map›Paper›PMID 28716301›Full record

ArticleSurgery2017

Discrete β-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia.

Shirin Hasan, Michael J Mosier, Andrea Szilagyi, Richard L Gamelli, Kuzhali Muthumalaiappan

Open access · greenAbstract read
In one paragraph

Article in Surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. The treatment of chronic anemia in heart failure: a global approach.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Review
  3. Review
  4. Article
  5. Transient Improvement in Erythropoiesis Is Achieved Via the Chaperone AHSP With Early Administration of Propranolol in Burn Patients.Journal of burn care & research : official publication of the American Burn Association · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shirin HasanDepartment of Surgery, Loyola University Chicago, Health Sciences Division, Maywood, IL; Burn and Shock Trauma Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL.
Michael J MosierDepartment of Surgery, Loyola University Chicago, Health Sciences Division, Maywood, IL; Burn and Shock Trauma Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL.
Andrea SzilagyiBurn and Shock Trauma Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL.
Richard L GamelliDepartment of Surgery, Loyola University Chicago, Health Sciences Division, Maywood, IL; Burn and Shock Trauma Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL.
Kuzhali MuthumalaiappanDepartment of Surgery, Loyola University Chicago, Health Sciences Division, Maywood, IL; Burn and Shock Trauma Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL. Electronic address: kmuthu@luc.edu.
Loyola University Chicago · US

Funding

Mechanisms of Impaired Erythropoiesis in Post Burn Anemia of Critical IllnessR01DK097760 · NIDDK · LOYOLA UNIVERSITY CHICAGO · PI MUTHUMALAIAPPAN, KUZHALI · 2013 to 2017
$1.1M
NIDDK NIH HHS R01 DK097760
6 · The paper itself

Abstract

backgroundAnemia of critical illness is resistant to exogenous erythropoietin. Packed red blood cells transfusions is the only treatment option, and despite related cost and morbidity, there is a need for alternate strategies. Erythrocyte development can be divided into erythropoietin-dependent and erythropoietin-independent stages. We have shown previously that erythropoietin-dependent development is intact in burn patients and the erythropoietin-independent early commitment stage, which is regulated by β1/β2-adrenergic mechanisms, is compromised. Utilizing the scald burn injury model, we studied erythropoietin-independent late maturation stages and the effect of β1/β2, β-2, or β-3 blockade in burn mediated erythropoietin-resistant anemia.

methodsBurn mice were randomized to receive daily injections of propranolol (nonselective β1/β2 antagonist), nadolol (long-acting β1/β2 antagonist), butoxamine (selective β2 antagonist), or SR59230A (selective β3 antagonist) for 6 days after burn. Total bone marrow cells were characterized as nonerythroid cells, early and late erythroblasts, nucleated orthochromatic erythroblasts and enucleated reticulocyte subsets using CD71, Ter119, and Syto-16 by flow cytometry. Multipotential progenitors were probed for MafB expressing cells.

resultsAlthough propranolol improved early and late erythroblasts, only butoxamine and selective β3-antagonist administrations were positively reflected in the peripheral blood hemoglobin and red blood cells count. While burn impeded early commitment and late maturation stages, β1/β2 antagonism increased the early erythroblasts through commitment stages via β2 specific MafB regulation. β3 antagonism was more effective in improving overall red blood cells through late maturation stages.

conclusionThe study unfolds novel β2 and β3 adrenergic mechanisms orchestrating erythropoietin resistant anemia after burn, which impedes both the early commitment stage and the late maturation stages, respectively.

Indexed as

ErythropoiesisAdrenergic AntagonistsAnemiaAnimalsBurnsButoxamineDisease Models, AnimalMaleMiceNadololPropanolaminesPropranololReceptors, Adrenergic, beta3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalateAdrenergic AntagonistsButoxamineNadololPropanolaminesPropranololReceptors, Adrenergic, beta

Identifiers

PMID28716301
PMCPMC5675564
OpenAlexW2735012447

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.